herpex 50 mg/g krem
sandoz gmbh - aciclovirum - krem - 50 mg/g
tabex 1,5 mg tabletki powlekane
sopharma warszawa sp. z o.o. - cytisinum - tabletki powlekane - 1,5 mg
tabex 1,5 mg tabletki powlekane
blau farma group sp. z o.o. - s.k.a. - tabletki powlekane - 1,5 mg
tabex 1,5 mg tabletki powlekane
inpharm sp. z o.o. - tabletki powlekane - 1,5 mg
tabex 1,5 mg tabletki powlekane
delfarma sp. z o.o. - tabletki powlekane - 1,5 mg
tabex 1,5 mg tabletki powlekane
pretium farm sp. z o.o. - cytisinum - tabletki powlekane - 1,5 mg
herpex 50 mg/g krem
inpharm sp. z o.o. - aciclovirum - krem - 50 mg/g
herpex 50 mg/g krem
medezin sp. z o.o. - aciclovirum - krem - 50 mg/g
kalydeco
vertex pharmaceuticals (ireland) limited - iwakaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 i 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
orkambi
vertex pharmaceuticals (ireland) limited - kombinaci lumacaftor, ivacaftor - zwłóknienie torbielowate - inne produkty układu oddechowego - tabletki orkambi są wskazane w leczeniu mukowiscydozy (cf) u pacjentów w wieku 6 lat i starszych, które są гомозиготами mutacji f508del w genie cftr . orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.